Updates to NCCN Guidelines on Molecular Assays for Patients With Breast CancerApril 8th 2019
William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.
Takeaways From TransATAC Trial on Comparing Prognostic SignaturesDecember 10th 2016
William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.